Bioqube Ventures
Overview
Specialist venture capital fund investing in European biotech companies.
Founded
2015
Deals · 12mo
1
Stage focus
Geographic focus
Sector focus
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Primmune Therapeutics | Jan 2026Participated | $9 MSeries B | |
Actithera | Jul 2025Participated | $76 MSeries A | |
Commit Biologics | Jan 2025Participated | $6 MSeed | |
SynOx Therapeutics | Oct 2024Participated | $92 MSeries B | |
Synox | Oct 2024Participated | $92 MSeries B | |
CatalYm | Jul 2024Led | $150 MSeries D | |
Commit Biologics | May 2024Participated | $17 MSeed | |
Anavo Therapeutics | May 2023Participated | $9 MSeed | |
Bicara Therapeutics | Mar 2023Participated | $108 MSeries B | |
Enhanc3D Genomics | Oct 2022Participated | $11 MSeries A | |
Tridek-One | Sep 2022Participated | $16 MOther Equity | |
Egle Therapeutics | Oct 2021Participated | $47 MSeries A | |
Primmune Therapeutics | Jan 2026Participated | $9 MSeries B | |
Actithera | Jul 2025Participated | $76 MSeries A | |
Commit Biologics | Jan 2025Participated | $6 MSeed | |
SynOx Therapeutics | Oct 2024Participated | $92 MSeries B | |
Synox | Oct 2024Participated | $92 MSeries B | |
CatalYm | Jul 2024Led | $150 MSeries D | |
Commit Biologics | May 2024Participated | $17 MSeed | |
Anavo Therapeutics | May 2023Participated | $9 MSeed | |
Bicara Therapeutics | Mar 2023Participated | $108 MSeries B | |
Enhanc3D Genomics | Oct 2022Participated | $11 MSeries A | |
Tridek-One | Sep 2022Participated | $16 MOther Equity | |
Egle Therapeutics | Oct 2021Participated | $47 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 4 |
| Series A | 1 | 3 |
| Series B | 0 | 4 |
| Series C+ | 1 | 0 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jan '21 | 1 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 1 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 1 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 1 |
| Oct '22 | 1 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 1 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 1 |
| Jun '24 | 0 |
| Jul '24 | 1 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 2 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 1 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 1 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 1 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 13 |
| Networks, Cloud & Communication | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 1 |
| $5M-$10M | 3 |
| $10M-$25M | 4 |
| $25M-$50M | 1 |
| $50M-$100M | 3 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| Europe | 11 |
| United States | 3 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Forbion | 3 |
| Gilde Healthcare | 3 |
| M Ventures | 3 |
| Bpifrance | 2 |
| HealthCap | 2 |
| INKEF Capital | 2 |
| Novo Holdings | 2 |
| Omega Funds | 2 |
| Taiho Ventures | 2 |
| 4BIO Capital | 1 |
| Acorn Bioventures | 1 |
| Advent France Biotechnology | 1 |
| Advent Life Sciences | 1 |
| Arkin Bio Ventures | 1 |
| BGF | 1 |
| Brandon Capital | 1 |
| Canaan Partners | 1 |
| Eight Roads Ventures | 1 |
| EQT Life Sciences (LSP) | 1 |
| F-Prime Capital | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 2 | 14% |
| Participating | 12 | 86% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 1 | 50% |
| Co-led | 1 | 50% |
Team
Co-Founder & Managing Partner
Managing Partner
Co-founder and Managing Partner